Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
15%
Antivirus Agent
13%
Cardiovascular Disease
7%
Clinical Trial
16%
Comorbidity
13%
Coronavirinae
14%
COVID-19 Vaccine
17%
Disease
25%
Drug Screening
8%
Glioblastoma
13%
Hydroxychloroquine
26%
Interferon
13%
Levodopa-Induced Dyskinesia
13%
Lopinavir
17%
Lopinavir Plus Ritonavir
15%
Messenger RNA
13%
Observational Study
13%
Overall Survival
8%
Parkinson's Disease
46%
Pharmacovigilance
13%
Progression Free Survival
8%
Randomized Controlled Trial
23%
Remdesivir
13%
Respiratory Tract Disease
13%
Respiratory Tract Infection
26%
SARS Coronavirus
30%
Xanthine
13%
Medicine and Dentistry
Booster Dose
17%
Cardiovascular Disease
7%
Cardiovascular System
13%
Comorbidity
13%
COVID-19
26%
COVID-19 Vaccine
16%
Disease
7%
Gut Microbiome
13%
Messenger RNA
11%
Metabolomics
13%
microRNA
13%
Mild Cognitive Impairment
13%
Observational Study
13%
Omicron Coronavirus Variant
13%
Parkinson's Disease
40%
Progressive Supranuclear Palsy
13%
Respiratory Disease
13%
Respiratory Tract Infection
26%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Neuroscience
Comorbidity
13%
Dyskinesia
26%
L-DOPA
26%
MicroRNA
13%
Mild Cognitive Impairment
26%
Parkinson's Disease
100%
Progressive Supranuclear Palsy
13%